Company Overview
Avalo Therapeutics, Inc. operates as a clinical stage biotechnology company dedicated to the development of therapies designed to treat immune dysregulation within the United States market. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry, where it pursues the creation of innovative treatments for complex immunological conditions. Its current market capitalization stands at $258.25M, while its annual revenue for the trailing twelve months is recorded at $59,000. The company employs an unspecified number of personnel, a metric listed as N/A in available data. The combination of a market cap exceeding $250 million and revenue in the low five-figure range suggests that the company is in an early-stage growth phase, relying on future clinical trial successes to drive significant value appreciation rather than current cash flow generation.
Financial Health
For the trailing twelve months, the company reported a revenue of $59,000, a net income of $-78,259,000, and an EBITDA of $-72,581,000. The substantial gap between the nominal revenue and the significant net loss reveals a cost structure dominated by research and development expenditures typical of clinical-stage biotechnology firms, where expenses far outpace immediate sales. Free cash flow for the period was $-17,263,124, indicating that the company is currently burning cash to fund its operations and clinical trials rather than generating liquidity. The gross margin is recorded at 0.0%, while the operating margin stands at -33461.0% and the profit margin is also 0.0%. These extreme negative margin figures highlight the pre-revenue nature of the business, where fixed operational costs and clinical trial expenses result in losses that disproportionately exceed sales figures. The company holds $98.34M in cash against a debt load of only $427,000, resulting in a debt-to-equity ratio of 0.51. This balance sheet structure is highly conservative, as the available cash reserves are sufficient to cover debt obligations many times over without requiring immediate external financing. Furthermore, the current ratio of 8.14 indicates robust short-term liquidity, demonstrating that the company possesses ample current assets to meet its short-term liabilities. Return on Equity is -72.4% and Return on Assets is -34.1%, metrics that reflect the inherent losses of a company in the clinical development phase where capital is being deployed to create future value rather than generating immediate returns on invested equity or assets.
Valuation Assessment
The trailing P/E ratio is N/A due to the absence of earnings, while the forward P/E is listed at -4.80. The negative forward P/E implies that the market expects earnings to remain negative in the near future, consistent with the company's current trajectory of operating losses during its clinical development stage. The price-to-book ratio is 3.11, suggesting that the market values the company's equity at a premium of over three times its book value, likely driven by the potential value of its pipeline assets and intellectual property rather than current financial performance. Alternative valuation metrics such as the price-to-sales ratio of 4377.17 and an EV/EBITDA of -3.03 further underscore the speculative nature of the stock, where valuation is disconnected from traditional profitability measures. The stock has traded between a 52-week low of $3.39 and a 52-week high of $20.72. Without a specific current share price provided in the facts, the valuation context is defined by this wide trading range, which reflects the high volatility inherent in clinical-stage biotech equities. The beta value is 0.89, indicating that the stock's price volatility is slightly lower than the broader market average, though it still exhibits significant fluctuation relative to standard market movements.
Growth & Income
Revenue growth year-over-year is recorded at -69.3%, while earnings growth year-over-year is N/A. The negative revenue growth suggests a contraction in sales or a shift in the revenue recognition model typical for a company transitioning from research to clinical trials where commercial sales are minimal or non-existent. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%. Consequently, the company reinvests all available capital and potential earnings back into research and development activities rather than distributing income to shareholders. This approach prioritizes the advancement of lead assets like AVTX-009 through phase 2 clinical trials over providing immediate income returns. The overall growth and income profile is characterized by negative revenue momentum and zero dividend distribution, reflecting a capital-intensive strategy focused on long-term asset development rather than short-term profitability or shareholder income.